WallStSmart

ICU Medical Inc (ICUI)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 1286% more annual revenue ($29.94B vs $2.16B). MDLN leads profitability with a 2.3% profit margin vs 1.4%. MDLN trades at a lower P/E of 42.6x. MDLN earns a higher WallStSmart Score of 52/100 (C-).

ICUI

Hold

50

out of 100

Grade: D+

Growth: 2.7Profit: 4.5Value: 7.3Quality: 6.5
Piotroski: 4/9Altman Z: 1.74

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 4.0Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.70
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICUIUndervalued (+53.7%)

Margin of Safety

+53.7%

Fair Value

$319.32

Current Price

$156.48

$162.84 discount

UndervaluedFair: $319.32Overvalued

Intrinsic value data unavailable for MDLN.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICUI2 strengths · Avg: 9.0/10
PEG RatioValuation
0.0810/10

Growing faster than its price suggests

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
262.0%10/10

Earnings expanding 262.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

ICUI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Altman Z-ScoreHealth
1.744/10

Distress zone — elevated risk

Return on EquityProfitability
2.2%3/10

ROE of 2.2% — below average capital efficiency

Profit MarginProfitability
1.4%3/10

1.4% margin — thin

MDLN4 concerns · Avg: 3.3/10
Altman Z-ScoreHealth
1.704/10

Distress zone — elevated risk

Return on EquityProfitability
6.0%3/10

ROE of 6.0% — below average capital efficiency

Profit MarginProfitability
2.3%3/10

2.3% margin — thin

Operating MarginProfitability
0.8%3/10

Operating margin of 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ICUI

The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.08 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 11.6% demonstrates continued momentum.

Bear Case : ICUI

The primary concerns for ICUI are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 135.3x leaves little room for execution misses. Thin 1.4% margins leave little buffer for downturns.

Bear Case : MDLN

The primary concerns for MDLN are Altman Z-Score, Return on Equity, Profit Margin. A P/E of 42.6x leaves little room for execution misses. Thin 2.3% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 11.6% — sustainability is the question.

MDLN generates stronger free cash flow (604M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 50/100) and 11.6% revenue growth. ICUI offers better value entry with a 53.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICU Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?